Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Indolent Non Hodgkin's Lymphoma (iNHL)”

Showing 8 of 0 results

Large-scale testing (Phase 3)Study completedNCT01500083
What this trial is testing

Bendamustine Hydrochloride (HCl) in Indolent Non-Hodgkin's Lymphoma That Has Progressed During or Following Treatment With a Rituximab Regimen or Previously Untreated Chronic Lymphocytic Leukemia

Who this might be right for
Indolent Non-Hodgkin's LymphomaChronic Lymphocytic Leukemia
Lundbeck Canada Inc. 90
Early research (Phase 1)Study completedNCT02417285
What this trial is testing

A Phase 1b Open-label Study to Evaluate the Safety and Efficacy of CC-122 With Obinutuzumab (GA101) in Relapsed/Refractory DLBCL and iNHL.

Who this might be right for
Lymphoma, Large B-Cell, DiffuseLymphoma, Non-Hodgkin
Celgene 75
Large-scale testing (Phase 3)Study completedNCT02369016
What this trial is testing

Phase III Copanlisib in Rituximab-refractory iNHL

Who this might be right for
Lymphoma, Non-Hodgkin
Bayer 25
Testing effectiveness (Phase 2)Ended earlyNCT02384954
What this trial is testing

QUILT-3.002: N-803 in Patients With Relapse/Refractory iNHL in Conjunction With Rituximab

Who this might be right for
Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphoma
Altor BioScience 43
Testing effectiveness (Phase 2)UnknownNCT05543070
What this trial is testing

Low-dose Radiotherapy in iNHL

Who this might be right for
Indolent LymphomaLow-dose Radiotherapy
Chinese Academy of Medical Sciences 73
Large-scale testing (Phase 3)Study completedNCT01974440
What this trial is testing

PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma

Who this might be right for
Lymphoma
Janssen Research & Development, LLC 403
Testing effectiveness (Phase 2)Study completedNCT03105336
What this trial is testing

Axicabtagene Ciloleucel in Participants With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

Who this might be right for
Follicular LymphomaMarginal Zone LymphomaIndolent Non-Hodgkin Lymphoma
Kite, A Gilead Company 159
Large-scale testing (Phase 3)Study completedNCT02367040
What this trial is testing

Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL)

Who this might be right for
Lymphoma,Non-Hodgkin
Bayer 458

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation